UK · Research-grade · Cold-chain

Retatrutide — the next-gen weight-loss peptide, what Phase 3 showed.

Everything tirzepatide does, plus a third lever — glucagon — that raises metabolic rate. Phase 3 is complete and the topline numbers are the largest in the class. Here's the honest picture: the data, the dosing, the glucagon side effects, and how to order it research-grade now.

01 · What it is

Triple agonist — the third lever is the whole story

One paragraph on the molecule, one on why the third pathway matters. Both from the product page.

In plain terms

Everything tirzepatide does — appetite suppression — plus a third lever, glucagon, which turns up your metabolic rate. You burn more on top of the same appetite suppression. That's the entire 'next-gen' claim in one sentence.

Technically

GLP-1R/GIPR/GCGR co-agonism (the TRAILBLAZER program, Eli Lilly). Glucagon-receptor activation increases energy expenditure — thermogenesis — and modulates hepatic glucose output.

02 · What Phase 3 showed

Evidence grade B — Phase 3 complete, approval pending as of 2026

The figures verbatim from the retatrutide product page. This is the most advanced triple agonist in the pipeline.

TRAILBLAZER-1

Roughly 24% mean body-weight loss at 48 weeks at 12 mg, per Phase 3 topline. For context: semaglutide's STEP-1 ran −14.9% at 68 weeks and tirzepatide's SURMOUNT-1 −20.9% to −22.5% at 72 weeks.

Where it sits

Evidence grade B — the data is Phase 3, the approval isn't in yet (2026 watch). The most advanced 'triple agonist' in the pipeline, which is exactly the niche it's supplied for.

03 · Dosing

The titration curve, as run in TRAILBLAZER

Typical research ranges from the product page — not a prescription.

StepDose (weekly)Note
Start4 mgEntry step of the TRAILBLAZER arms.
Step 28 mgMid-curve.
Top12 mgThe arm that produced the ~24% @48wk topline figure.
The hedge, every time: typical research/clinical ranges — not a prescription. Our RT vials (5–15 mg × 10) support the full titration curve, so one vial covers the whole run.
04 · Side effects

What the glucagon pathway adds

From the product page. The GI profile is class-typical; the heart-rate effect is the one to know about before you start.

1
GI: nausea, diarrhoea

Class-typical — similar to semaglutide and tirzepatide. The product page's own FAQ puts it at 'similar GI tolerability' to the dual agents.

2
Small resting-heart-rate increase

This is the glucagon effect — a mild increase, noted in the product page FAQ. It's the honest price of the third pathway.

3
Rare gallstones

On the list, low frequency. Same category as the other agents in the class.

05 · Ordering

How to order it research-grade now

Per-vial pricing, two payment paths, same delivery as the rest of the range.

1
Per-vial pricing, no minimums

RT vials (5–15 mg × 10) support the full titration curve — order one vial or a full course, the per-vial price is the same.

2
Bank transfer — save 10%

Same lot, same delivery, whole order 10% off. Quote your order number as the payment reference.

3
COA in the box, cold-chain to your door

Every batch ships with its Certificate of Analysis — tracked, insured, UK-wide, next working day dispatch. WELCOME10 stacks on your first order.

Research-use positioning: supplied from GMP-grade sources with a COA in the box. Not a licensed medicine and not for direct human consumption. Dosing shown = typical research/clinical ranges, not a prescription.
06 · Straight answers

The questions people actually ask

How is retatrutide different from tirzepatide?
It adds a third pathway — glucagon — which raises metabolic rate and energy expenditure on top of the appetite suppression. In trials that's more weight loss at similar GI tolerability, per the product page.
What did Phase 3 actually show?
TRAILBLAZER-1: roughly 24% mean body-weight loss at 48 weeks at 12 mg, per Phase 3 topline. Evidence grade B — Phase 3 complete, approval pending as of 2026. That's the honest state of the evidence.
Is it approved yet?
Phase 3 is complete; it's on the 2026 approval watch. That's why we supply it research-grade now — for researchers and early adopters ahead of launch.
What side effects come with the glucagon pathway?
GI effects similar to the rest of the class — nausea, diarrhoea — plus a small increase in resting heart rate from the glucagon effect, and rare gallstones. Class-typical GI profile, per the product page.
How do I dose it in a research cycle?
Typical: 4 mg weekly start, titrating to 8 / 12 mg (the TRAILBLAZER arms). Typical research ranges — not a prescription. Our RT vials (5–15 mg × 10) support the full titration curve.
07 · Don't miss a restock

Restock alerts + first-order tips, no list-of-emails

One useful email when a vial needs replacing, plus the bits that save you the vial. No pressure, unsubscribe anytime.